Cobra Biologics, an international CMDO manufacturer of biologic materials and pharmaceuticals has successfully produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01. This represents a further milestone in the future commercial manufacture of a drug candidate designed for the treatment of drug-resistant focal epilepsy.      The three master cell banks have been developed according to Good Manufacturing Practice (GMP). GMP-compliant cell bank...